equities

U.S. benchmarks were pointing higher this morning ahead of both the bell and a long weekend. Tomorrow brings Nonfarm Payroll, but the NYSE is closed and index futures only trade through 8:15 a.m. CT due to the Good Friday holiday.
With a melting pot of narratives, this quarter brought a lot of chop, but at the end of the day, the trend is higher, the fundamentals are supportive, and there’s no reason to believe either will dissipate, at least not through April.
With Europeans in lockdown and the U.S. seeing a successful vaccine rollout, there’s a tailwind to both the U.S. Dollar and Treasury rates. The latter adds strength to the former.
Each day on the European market opening Anthony Cheung, Sam North, and Amplify Trading gets you prepared for the trading day. They focus on relevant macroeconomic insights and trade idea generation for the global macro futures markets.
Constructive hold of support early in Thursday's session set the stage for a friendly Friday. This undeniably brought bullish technical tailwinds due to seller’s exhaustion, shorts covering, and fresh buying hitting the tape. Remember, this is a bull market.
Early signs of strength across each index dissipated as the session unfolded; the Nasdaq was first to go, slammed at the opening bell, then the Russell midday. The S&P followed, and the Dow was the last— although the Dow finished positive by 13 ticks, it was 1% from its session high. 
Like Monday, rally attempts in the S&P and Nasdaq were deflected by strong levels of technical resistance. From there, each bled slowly leading up to the final hour.
Late last night, a U.S. health agency questioned the validity of AstraZeneca’s vaccine trials, saying the results included outdated data. To make matters worse, Germany followed through and announced a strict 5-day lockdown over Easter.
Each day on the European market opening Anthony Cheung, Sam North, and Amplify Trading gets you prepared for the trading day. They focus on relevant macroeconomic insights and trade idea generation for the global macro futures markets.
The vaccine was suspended throughout the EU after concerns it caused blood clots. Trials across the U.S., Chile, and Peru showed the vaccine 79% effective with no link to blood clots. This comes after the European Medicines Agency confirmed similar findings last Thursday.